GlassScriptPhysician profile
James Sayegh
NPI 1326452186
$20,018.74
in general payments reported to CMS, 2019-2025
67 companies · $3,209 in 2025
The $3,209 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $2,345 · 2021: $2,133 · 2022: $2,948 · 2023: $4,465 · 2024: $3,811 · 2025: $3,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $70.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,414.28 |
| Education | $70.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,587.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,511.57 | 2019-2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $1,452.66 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,426.92 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $1,244.63 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $1,084.45 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,021.33 | 2019-2024 | Linzess, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $981.14 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $852.56 | 2022-2025 | |
| Abbott Laboratories | $729.00 | 2020-2025 | Freestyle Libre 3, Cardiomems, Freestyle Libre |
| Boston Scientific Corporation | $718.50 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian, Emblem Mri S-Icd |
| Amarin Pharma, INC. | $674.37 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $641.54 | 2023-2025 | Gemtesa, Myfembree |
| Pfizer INC. | $507.47 | 2023-2025 | |
| Aytu Biopharma, INC. | $468.19 | 2019-2020 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.